impact factor
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Plasma pentraxin-3 levels in patients with Takayasu’s arteritis during routine follow-up

1, 2, 3, 4, 5, 6

 

  1. Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey. falibaz@gmail.com
  2. Ege University, School of Medicine, Division of Rheumatology, Izmir, Turkey.
  3. Istanbul University, Istanbul Medical Faculty, Department of Physiology, Istanbul, Turkey.
  4. Ege University, School of Medicine, Division of Rheumatology, Izmir, Turkey.
  5. Istanbul University, Istanbul Medical Faculty, Department of Physiology, Istanbul, Turkey.
  6. Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey.

CER9005
2016 Vol.34, N°3 ,Suppl.97
PI 0073, PF 0076
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 26885720 [PubMed]

Received: 28/09/2015
Accepted : 23/11/2015
In Press: 05/02/2016
Published: 27/05/2016

Abstract

OBJECTIVES:
To date, no biomarker is universally accepted to be a surrogate for active disease being one of major difficulties in follow-up of Takayasu’s arteritis (TAK). In this study, we aimed to investigate plasma pentraxin-3 (PTX-3) levels and its correlation with activity in patients with TAK.
METHODS:
This cross-sectional study included 94 patients (age: 43.3±13.6 years, F/M: 80/14) with TAK, 40 age-sex matched control donors (age: 41.5±9.3 years, F/M: 28/12). TAK patients were evaluated by physician’s global assessment (PGA; active/inactive), as well as with the activity definition by Kerr et al. and with a new composite index of ITAS2010 (Indian Takayasu Clinical Activity Score). Plasma PTX-3 levels are measured with an enzyme linked immunosorbent assay kit.
RESULTS:
Thirty-three (35.5%) patients were clinically active with PGA, while 25 (31.6%) patients and 28 (31.8%) patients were accepted to have active disease according to Kerr activity criteria and ITAS2010, respectively. Plasma PTX-3 levels were significantly higher in TAK patients compared to healthy controls (3.5±2.5 ng/ml vs. 2.5±1.6 ng/ ml, p=0.029). However, PTX-3 levels were similar among active and inactive patients according to all three assessment tools. PTX-3 levels significantly correlated only with serum CRP levels.
CONCLUSIONS:
Although plasma PTX- 3 levels were higher in patients with TAK compared to healthy controls, we observed no association with disease activity, limiting the role of PTX-3 level as a biomarker for active disease in TAK.

Rheumatology Article